ORIC - oricpharma.com Price to Earnings Adjusted for Growth Rate

Symbol and logo of brand ORIC Pharmaceuticals (ORIC)

ORIC Pharmaceuticals is carving out a narrow niche in combating tumor resistance, aiming for market dominance should its drug candidates succeed. The scientific foundation enables the creation of combination regimens that bypass cancer cell defenses. Risks are minimized by distributing trials across external laboratories. The ratio of the company's valuation to its growth rate on this chart visualizes the fundamental trend, while the 0.00 indicator confirms the current level.

ORIC: oricpharma.com Price/Earnings to Growth Multiple 07/04/2022 - 11/10/2026

Metric breakdowns and analytics for ORIC Pharmaceuticals (ORIC)

- market value and analyst target forecast:
Price Rate Chart ORIC Pharmaceuticals Inc|ORIC - Consensus Target
- market capitalization statistics:
Market Value ORIC Pharma|ORIC - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Accounting Value of a Share ORIC Pharmaceuticals|ORIC - Company Net Assets|Market Cap to Book Value Multiple oricpharma.com|ORIC - Company Total Assets
- business debt structure and liquidity details:
Total Debt to Capital ORIC Pharmaceuticals|ORIC - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital oricpharma.com|ORIC - Company Aggregate Debts|Debt to Net Assets ORIC Pharma|ORIC - Company Long-Term Debts|Short-Term Debt ORIC Pharmaceuticals|Intermediate Liquidity Ratio oricpharma.com
- earnings and valuation multiples information:
ORIC - Net Profit|Expected Net Profit ORIC Pharmaceuticals|ORIC - P/E Multiple|Price to Future Earnings Ratio ORIC Corp|ORIC - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation ORIC Pharma|ORIC - Operating profit before deduction of amortization|Earnings per share for the last four quarters ORIC Pharmaceuticals|ORIC - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months oricpharma.com|ORIC - Earnings growth in current year|Expected net earnings per share growth next year ORIC Pharmaceuticals
General company analysis:ORIC Pharmaceuticals
Signature product of oricpharma.com

Amid market volatility, capital protection requires distinguishing between true undervaluation and business degradation. The focus of ORIC Pharmaceuticals (ORIC) on laboratory safety and clinical trials minimizes operational risks, while the PEG ratio—dividing the P/E by the earnings growth rate—identifies undervalued assets when the value is below one, signaling potential for a sharp surge in share prices.

Competing companies

Genmab AS (GMAB) - Price to Net Income Growth Ratio|Exelixis Corp - Price/Earnings to Growth Multiple|Nuvalent Therapeutics (NUVL) - Price to Earnings Adjusted for Growth Rate|KYMR: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio IDYA (ideayabio.com)|ELVN (Enliven Therapeutics, Inc.) - Price/Earnings to Growth Multiple|RLAY: Company Value to Earnings Growth Ratio|NRIX (Nurix Pharma) - PEG Multiple|PEG Multiple Tyra Corp|Price/Earnings to Growth Ratio Verastem, Inc. (VSTM)|GLUE (monterosatx.com) - Growth-Adjusted Payback Ratio|PEG Multiple CGEM (Cullinan Therapeutics, Inc.)|Price to Net Income Growth Ratio Immuneering Corp|C4 Tx - PEG Multiple|Price to Earnings Adjusted for Growth Rate Black Diamond Therapeutics, Inc|RPTX (Repare Therapeutics) - Price/Earnings to Growth Multiple|PMVP: Company Value to Earnings Growth Ratio|KPTI (Karyopharm Therapeutics, Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Propanc Biopharma, Inc. PPCB|PEG Multiple BGMS|aadibio.com - Growth-Adjusted P/E Ratio|Aileron Therapeutics, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio BPMC|GLYC: Price/Earnings to Growth Multiple|SpringWorks Therapeutics Inc. - Company Value to Earnings Growth Ratio